Anti-atherosclerotic effect of repaglinide or glimepiride in Japanese type 2 diabetic patients

Trial Profile

Anti-atherosclerotic effect of repaglinide or glimepiride in Japanese type 2 diabetic patients

Discontinued
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Glimepiride (Primary) ; Repaglinide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 11 Aug 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 13 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top